CN109156830A - 一种改善餐后血糖和调节肠道微生态的组合物 - Google Patents
一种改善餐后血糖和调节肠道微生态的组合物 Download PDFInfo
- Publication number
- CN109156830A CN109156830A CN201810902409.0A CN201810902409A CN109156830A CN 109156830 A CN109156830 A CN 109156830A CN 201810902409 A CN201810902409 A CN 201810902409A CN 109156830 A CN109156830 A CN 109156830A
- Authority
- CN
- China
- Prior art keywords
- blood sugar
- postprandial blood
- composition
- intestinal microecology
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 83
- 210000004369 blood Anatomy 0.000 title claims abstract description 83
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 76
- 230000000291 postprandial effect Effects 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 239000011782 vitamin Substances 0.000 claims abstract description 16
- 229940088594 vitamin Drugs 0.000 claims abstract description 16
- 229930003231 vitamin Natural products 0.000 claims abstract description 16
- 235000013343 vitamin Nutrition 0.000 claims abstract description 16
- 102000040350 B family Human genes 0.000 claims abstract description 14
- 108091072128 B family Proteins 0.000 claims abstract description 14
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 13
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 9
- 244000013123 dwarf bean Species 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 8
- 235000021278 navy bean Nutrition 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 6
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 28
- 235000013399 edible fruits Nutrition 0.000 claims description 12
- 235000013365 dairy product Nutrition 0.000 claims description 10
- 235000003599 food sweetener Nutrition 0.000 claims description 10
- 239000003765 sweetening agent Substances 0.000 claims description 10
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 5
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 5
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 5
- 235000021014 blueberries Nutrition 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 27
- 235000016709 nutrition Nutrition 0.000 abstract description 18
- 235000005911 diet Nutrition 0.000 abstract description 12
- 230000037213 diet Effects 0.000 abstract description 12
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 11
- 230000009286 beneficial effect Effects 0.000 abstract description 10
- 239000004615 ingredient Substances 0.000 abstract description 10
- 241000894006 Bacteria Species 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 9
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 8
- 230000002757 inflammatory effect Effects 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- 238000010586 diagram Methods 0.000 description 15
- 230000006872 improvement Effects 0.000 description 13
- 235000013305 food Nutrition 0.000 description 10
- 241000219000 Populus Species 0.000 description 9
- 108010074051 C-Reactive Protein Proteins 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102100037505 Secretin Human genes 0.000 description 4
- 108010086019 Secretin Proteins 0.000 description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 229960002101 secretin Drugs 0.000 description 4
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011546 CRP measurement Methods 0.000 description 3
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 3
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 244000228451 Stevia rebaudiana Species 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Natural products CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical group O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 238000006701 autoxidation reaction Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000003890 endocrine cell Anatomy 0.000 description 2
- 230000007368 endocrine function Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229940083592 glimepiride 1 mg Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940107604 lutein esters Drugs 0.000 description 2
- 150000002658 luteins Chemical class 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010062198 microangiopathy Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- VOMXSOIBEJBQNF-UTTRGDHVSA-N novorapid Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 VOMXSOIBEJBQNF-UTTRGDHVSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 244000086443 Craterellus fallax Species 0.000 description 1
- 235000007926 Craterellus fallax Nutrition 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- -1 Flavine ester Chemical class 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供的改善餐后血糖并可调节肠道微生态的组合物,设置按重量份数的原料组分为:7~10份水溶性膳食纤维、5~8份白芸豆提取物、1~3份B族维生素以及1~3份叶黄素酯;这样的组合物克服了现有技术中的食疗营养制剂辅助降糖效果不明显、营养成分不充足的问题,可以改善餐后血糖;同时增加肠道有益菌,调整肠道微生态,消除肠道炎症,改善糖尿病患者胰岛素抵抗。
Description
技术领域
本发明涉及保健食品领域,尤其涉及一种改善餐后血糖和调节肠道微生态的组合物。
背景技术
血中的葡萄糖称为血糖(Glu)。葡萄糖是人体的重要组成成分,也是能量的重要来源。正常人体每天需要从食物中摄取葡萄糖来提供足够的能量,为各种组织、脏器的正常运作提供动力。所以血糖必须保持一定的水平才能维持体内各器官和组织的需要。正常人血糖的产生和利用处于动态平衡的状态,维持在一个相对稳定的水平,这是由于血糖的来源和去路大致相同的结果。血糖的来源包括:①食物消化、吸收;②肝内储存的糖原分解;③脂肪和蛋白质的转化。血糖的去路包括:①氧化转变为能量;②转化为糖原储存于肝脏、肾脏和肌肉中;③转变为脂肪和蛋白质等其他营养成分加以储存。胰岛是体内调节血糖浓度的主要器官,肝脏储存肝糖元。此外,血糖浓度还受神经、内分泌激素的调节。
糖尿病是一组以高血糖为特征的代谢性疾病,高血糖则是由于胰岛素分泌缺陷或其生物作用受损,或两者兼有引起,糖尿病是长期存在的高血糖,导致各种组织,特别是心、眼、肾、血管、神经的慢性损害、功能障碍,糖尿病可以引起多种并发症,如果糖尿病没有得到足够的控制,可以引起一些急性并发症,如低血糖症、酮症酸中毒、非酮高渗性昏迷,严重的长期并发症包括:心血管疾病、慢性肾衰竭、视网膜病变、神经病变及微血管病变,其中,微血管病变可能导致勃起功能障碍以及伤口难以愈合,而足部难以愈合的伤口则可能导致坏疽,进而导致患者截肢,如果糖尿病得到了足够的控制,并且对血压充分控制并结合良好的生活习惯,则可以在有效的降低罹患上述并发症的危险。
“药食同源”是中华原创医学之中对人类最有价值的贡献之一;中医历来强调“药疗不如食疗”,食疗成为现代人追求返璞归真、健康饮食的最佳选择;让人们在享受美食的过程中祛除病痛,保健身体。尤其针对糖尿病患者,在治疗过程中,饮食的调整配合十分重要,直接关系到患者的病情发展。
现有技术中,为了使糖尿病患者在配合降糖药物或注射胰岛素的同时,更好的配合饮食情况,糖尿病患者会通过食用市售的营养制剂来配合降糖。但是现有技术中针对糖尿病患者的营养制剂由于考虑到糖尿病人的特殊体质,其在原料配伍时存在营养成分不充足、辅助降糖效果不明显的问题。
发明内容
针对上述存在的问题,本发明提供的一种改善餐后血糖并可调节肠道微生态的组合物,以克服现有技术中的食疗营养制剂辅助降糖效果不明显、营养成分不充足的问题,可以改善餐后血糖;同时增加肠道有益菌,调整肠道微生态,消除肠道炎症,改善糖尿病患者胰岛素抵抗。
为了实现上述目的,本发明采取的技术方案为:
一种改善餐后血糖并可调节肠道微生态的组合物,其中,包括以下重量份数的原料组分:7~10份水溶性膳食纤维、5~8份白芸豆提取物、1~3份B族维生素以及1~3份叶黄素酯。
上述的改善餐后血糖并可调节肠道微生态的组合物,其中,所述B族维生素的配比为:B1:B2:B6:B12=1~3:1~2:1~3:2~4。
上述的改善餐后血糖并可调节肠道微生态的组合物,其中,采用如上述的改善餐后血糖并可调节肠道微生态的组合物制成的产品为压片、固体饮料、硬胶囊中的一种或多种。
上述的改善餐后血糖并可调节肠道微生态的组合物,其中,采用如上述的改善餐后血糖并可调节肠道微生态的组合物制成的产品中添加有0.2-05份的甜味剂、0.2-05份的乳制品、0.2-05份的水果粉中的一种或多种。
上述的改善餐后血糖并可调节肠道微生态的组合物,其中,所述甜味剂为甜菊糖或三氯蔗糖。
上述的改善餐后血糖并可调节肠道微生态的组合物,其中,所述乳制品为乳粉。
上述的改善餐后血糖并可调节肠道微生态的组合物,其中,所述水果粉为蓝莓粉或混合水果粉。
上述技术方案具有如下优点或者有益效果:
本发明提供的改善餐后血糖并可调节肠道微生态的组合物,设置按重量份数的原料组分为:7~10份水溶性膳食纤维、5~8份白芸豆提取物、1~3份B族维生素以及1~3份叶黄素酯;这样的组合物一方面抑制肠内的α-淀粉酶的活力,阻碍人体对食物中碳水化合物的水解和消化,降低食物中淀粉糖类物质的分解吸收,抑制餐后血糖的升高,有利于糖尿病患者的血糖控制;另一方面,使小肠中未消化的淀粉成为抗性糊精,结合水溶性膳食纤维,促进有益菌的增殖,调节肠道微生态,肠道菌群的代谢产物,如短链脂肪酸、吲哚及胆汁酸等物质,能够消除体内炎症,调节肠道的内分泌功能,从而影响血糖。
并且这样的组合物能够使肠道上皮细胞中的内分泌细胞合成肠促胰素,肠促胰素调控胰岛β细胞,能够促进胰岛素的合成并改善β细胞对血糖的反应性。肠道的改善会提高胰岛素敏感性,改善2型糖尿病患者胰岛素抵抗;抑制细胞脂质的自动氧化和防止氧化带来的细胞损伤,对于预防和延缓糖尿病的慢性并发症有重要作用。而组合物中由于添加了B族维生素,B族维生素作为关键酶的辅酶,在糖代谢中起重要作用,可减少糖尿病性神经病变,降低糖尿病患者心血管并发症的发病风险。
本发明提供的改善餐后血糖并可调节肠道微生态的组合物克服了现有技术中的食疗营养制剂辅助降糖效果不明显、营养成分不充足的问题,可以改善餐后血糖;同时增加肠道有益菌,调整肠道微生态,消除肠道炎症,改善糖尿病患者胰岛素抵抗。
附图说明
通过阅读参照以下附图对非限制性实施例所作的详细描述,本发明及其特征、外形和优点将会变得更加明显。在全部附图中相同的标记指示相同的部分。并未刻意按照比例绘制附图,重点在于示出本发明的主旨。
图1是何某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的糖化血红蛋白检验报告的对比示意图;
图2是何某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的餐后三小时葡萄糖检验报告的对比示意图;
图3是何某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的超敏C反应蛋白测定报告的对比示意图;
图4是何某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的谷氨酰转肽酶检验报告的对比示意图;
图5是何某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的尿微量白蛋白及尿微肌酐比值检验报告的对比示意图;
图6是荀某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的糖化血红蛋白检验报告的对比示意图;
图7是荀某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的餐后三小时葡萄糖检验报告的对比示意图;
图8是荀某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的超敏C反应蛋白测定报告的对比示意图;
图9是荀某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的谷氨酰转肽酶检验报告的对比示意图;
图10是荀某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的尿微量白蛋白及尿微肌酐比值检验报告的对比示意图;
图11是杨某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的糖化血红蛋白检验报告的对比示意图;
图12是杨某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的餐后三小时葡萄糖检验报告的对比示意图;
图13是杨某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的超敏C反应蛋白测定报告的对比示意图;
图14是杨某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的谷氨酰转肽酶检验报告的对比示意图;
图15是杨某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物两个月前后的尿微量白蛋白及尿微肌酐比值检验报告的对比示意图。
具体实施方式
下面结合附图和具体的实施例对本发明作进一步的说明,但是不作为本发明的限定。
实施例1:
本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物包括以下重量份数的原料组分:8份水溶性膳食纤维、5份白芸豆提取物、2份B族维生素以及2份叶黄素酯;其中,B族维生素的配比为:B1:B2:B6:B12=2:1:2:3。
本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物制成的产品为粉末,该粉末中添加有0.3份的甜味剂、0.3份的乳制品和0.3份的水果粉中;甜味剂为甜菊糖;乳制品为乳粉;水果粉为蓝莓粉。
在临床中,何某,男,71岁,糖尿病病龄5年,干预前每周4-5天服用二甲双胍且每天一片、每周2-3天服用拜糖平且每天1片、每周2-3天服用力贻苹格列美脲1mg且每天1片;干预后服用力贻苹格列美脲1mg每天半片。患者自我管理能力较好,饮食较为丰富。
上述的干预是指:何某食用本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物。
对何某干预前和干预后的各项指标进行了检验,参见下表1和图1~图5:表1:何某的各项指标干预前和干预后的对比表
从上表1和图1~图5中可以得知:
①糖化(HbA1c)与血糖:干预期间血糖稳定,HbA1c下降,显示最近2个月血糖控制稳定。
②超敏C反应蛋白(由3降到<1),炎症得到改善。
③肝肾功能:体检结果显示,干预后肝肾功能损伤指标明显有好转。
由此可见,本本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物克服了现有技术中的食疗营养制剂辅助降糖效果不明显、营养成分不充足的问题,可以改善餐后血糖;同时增加肠道有益菌,调整肠道微生态,消除肠道炎症,改善糖尿病患者胰岛素抵抗。
实施例2:
本发明实施例2提供的改善餐后血糖并可调节肠道微生态的组合物包括以下重量份数的原料组分:9份水溶性膳食纤维、5份白芸豆提取物、3份B族维生素以及2份叶黄素酯;其中,B族维生素的配比为:B1:B2:B6:B12=3:2:3:4。
本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物制成的产品为粉末,该粉末中添加有0.3份的甜味剂、0.3份的乳制品和0.3份的水果粉中;甜味剂为甜菊糖;乳制品为乳粉;水果粉为蓝莓粉。
在临床中,荀某,男,48岁,糖尿病病龄14年,干预前服用诺和锐门冬30-31U/天(早16U,晚15U)、拜唐苹4粒/天(早1,中2,晚1),干预后服用诺和锐门冬30-32U/天(早17U,晚15U),停止服用拜唐苹。临床期间依从性较好,但干预中作息时间不规律,饮食上喜食糯性、油炸类食物。
上述的干预是指:荀某食用本本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物。
对荀某干预前和干预后的各项指标进行了检验,参见下表2和图6~图10:表2:荀某的各项指标干预前和干预后的对比表
从上表2和图6~图10中可以得知:
①糖化(HbA1c)与血糖:与干预前相比糖化明显下降,空腹和餐后血糖持续下降,显示血糖管理改善。
②超敏C反应蛋白(由3降到<1),炎症得到改善。
③肝肾功能无明显变化。
由此可见,本本发明实施例2提供的改善餐后血糖并可调节肠道微生态的组合物克服了现有技术中的食疗营养制剂辅助降糖效果不明显、营养成分不充足的问题,可以改善餐后血糖;同时增加肠道有益菌,调整肠道微生态,消除肠道炎症,改善糖尿病患者胰岛素抵抗。
实施例3:
本发明实施例3提供的改善餐后血糖并可调节肠道微生态的组合物包括以下重量份数的原料组分:10份水溶性膳食纤维、7份白芸豆提取物、2份B族维生素以及2份叶黄素酯;其中,B族维生素的配比为:B1:B2:B6:B12=3:2:3:4。
本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物制成的产品为粉末,该粉末中添加有0.2份的甜味剂、0.2份的乳制品和0.2份的水果粉中;甜味剂为甜菊糖;乳制品为乳粉;水果粉为蓝莓粉。
在临床中,杨某,女,70岁,糖尿病病龄3-4年,干预前格列美脲早1粒/天,干预过程中用药无变化。临床期间依从性较好,但饮食上喜欢吃肥腻、糯性食物,主食量偏多,运动偏少。
上述的干预是指:杨某食用本本发明实施例1提供的改善餐后血糖并可调节肠道微生态的组合物。
对杨某干预前和干预后的各项指标进行了检验,参见下表3和图11~图15:表3:杨某的各项指标干预前和干预后的对比表
从上表3和图11~图15中可以得知:
①糖化(HbA1c)与血糖:与干预前相比糖化明显下降,空腹和餐后血糖持续下降,显示血糖管理改善。
②超敏C反应蛋白(由7降到<1),炎症有明显的改善。
③肝肾功能:体检结果显示,干预后肝肾功能损伤指标明显有好转。
由此可见,本本发明实施例3提供的改善餐后血糖并可调节肠道微生态的组合物克服了现有技术中的食疗营养制剂辅助降糖效果不明显、营养成分不充足的问题,可以改善餐后血糖;同时增加肠道有益菌,调整肠道微生态,消除肠道炎症,改善糖尿病患者胰岛素抵抗。
综上所述,本发明实施例提供的改善餐后血糖并可调节肠道微生态的组合物,设置按重量份数的原料组分为:7~10份水溶性膳食纤维、5~8份白芸豆提取物、1~3份B族维生素以及1~3份叶黄素酯;这样的组合物一方面抑制胃肠内的α-淀粉酶的活力,阻碍人体对食物中碳水化合物的水解和消化,降低食物中淀粉糖类物质的分解吸收,抑制餐后血糖的升高,有利于糖尿病患者的血糖控制;另一方面,使小肠中未消化的淀粉成为抗性糊精,促进有益菌的增殖,调节肠道微生态,肠道菌群的代谢产物,如短链脂肪酸、吲哚及胆汁酸等物质,能够消除体内炎症,调节肠道的内分泌功能,从而影响血糖。
并且这样的组合物能够使肠道上皮细胞中的内分泌细胞合成肠促胰素,肠促胰素调控胰岛β细胞,能够促进胰岛素的合成并改善β细胞对血糖的反应性。肠道的改善会提高胰岛素敏感性,改善2型糖尿病患者胰岛素抵抗;抑制细胞脂质的自动氧化和防止氧化带来的细胞损伤,对于预防和延缓糖尿病的慢性并发症有重要作用。而组合物中由于添加了B族维生素,B族维生素作为关键酶的辅酶,在糖代谢中起重要作用,可减少糖尿病性神经病变,并降低同型半胱氨酸水平,降低糖尿病患者心血管并发症的发病风险。
本发明提供的改善餐后血糖并可调节肠道微生态的组合物克服了现有技术中的食疗营养制剂辅助降糖效果不明显、营养成分不充足的问题,可以改善餐后血糖;同时增加肠道有益菌,调整肠道微生态,消除肠道炎症,改善糖尿病患者胰岛素抵抗。
本领域技术人员应该理解,本领域技术人员结合现有技术以及上述实施例可以实现所述变化例,在此不予赘述。这样的变化例并不影响本发明的实质内容,在此不予赘述。
以上对本发明的较佳实施例进行了描述。需要理解的是,本发明并不局限于上述特定实施方式,其中未尽详细描述的设备和结构应该理解为用本领域中的普通方式予以实施;任何熟悉本领域的技术人员,在不脱离本发明技术方案作出许多可能的变动和修饰,或修改为等同变化的等效实施例,这并不影响本发明的实质内容。因此,凡是未脱离本发明技术方案的内容,依据本发明的技术实质对以上实施例所做的任何简单修改、等同变化及修饰,均仍属于本发明技术方案保护的范围内。
Claims (7)
1.一种改善餐后血糖并可调节肠道微生态的组合物,其特征在于,包括以下重量份数的原料组分:7~10份水溶性膳食纤维、5~8份白芸豆提取物、1~3份B族维生素以及1~3份叶黄素酯。
2.如权利要求1所述的改善餐后血糖并可调节肠道微生态的组合物,其特征在于,所述B族维生素的配比为:B1:B2:B6:B12=1~3:1~2:1~3:2~4。
3.如权利要求1所述的改善餐后血糖并可调节肠道微生态的组合物,其特征在于,采用如权利要求1或2所述的改善餐后血糖并可调节肠道微生态的组合物制成的产品为压片、固体饮料、硬胶囊中的一种或多种。
4.如权利要求3所述的改善餐后血糖并可调节肠道微生态的组合物,其特征在于,采用如权利要求1或2所述的改善餐后血糖并可调节肠道微生态的组合物制成的产品中添加有0.2-05份的甜味剂、0.2-05份的乳制品、0.2-05份的水果粉中的一种或多种。
5.如权利要求4所述的改善餐后血糖并可调节肠道微生态的组合物,其特征在于,所述甜味剂为甜菊糖或三氯蔗糖。
6.如权利要求4所述的改善餐后血糖并可调节肠道微生态的组合物,其特征在于,所述乳制品为乳粉。
7.如权利要求4所述的改善餐后血糖并可调节肠道微生态的组合物,其特征在于,所述水果粉为蓝莓粉或混合水果粉。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810902409.0A CN109156830A (zh) | 2018-08-09 | 2018-08-09 | 一种改善餐后血糖和调节肠道微生态的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810902409.0A CN109156830A (zh) | 2018-08-09 | 2018-08-09 | 一种改善餐后血糖和调节肠道微生态的组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109156830A true CN109156830A (zh) | 2019-01-08 |
Family
ID=64895319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810902409.0A Pending CN109156830A (zh) | 2018-08-09 | 2018-08-09 | 一种改善餐后血糖和调节肠道微生态的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109156830A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006325486A (ja) * | 2005-05-26 | 2006-12-07 | Akira Matsuo | 機能性食品および機能性飲料 |
CN106360310A (zh) * | 2016-10-12 | 2017-02-01 | 糖友管家(北京)健康管理有限公司 | 一种降低餐后血糖的组合物及其应用 |
CN107006744A (zh) * | 2017-03-16 | 2017-08-04 | 河北以岭医药研究院有限公司 | 一种白芸豆固体饮料及其制备工艺 |
CN108112996A (zh) * | 2017-12-12 | 2018-06-05 | 法尔玛国际健康管理有限公司 | 一种控制2型糖尿病人群高血糖和提高免疫力的营养组合物 |
-
2018
- 2018-08-09 CN CN201810902409.0A patent/CN109156830A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006325486A (ja) * | 2005-05-26 | 2006-12-07 | Akira Matsuo | 機能性食品および機能性飲料 |
CN106360310A (zh) * | 2016-10-12 | 2017-02-01 | 糖友管家(北京)健康管理有限公司 | 一种降低餐后血糖的组合物及其应用 |
CN107006744A (zh) * | 2017-03-16 | 2017-08-04 | 河北以岭医药研究院有限公司 | 一种白芸豆固体饮料及其制备工艺 |
CN108112996A (zh) * | 2017-12-12 | 2018-06-05 | 法尔玛国际健康管理有限公司 | 一种控制2型糖尿病人群高血糖和提高免疫力的营养组合物 |
Non-Patent Citations (1)
Title |
---|
刘莹: "《本草中的食物养生》", 30 June 2016 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108112996A (zh) | 一种控制2型糖尿病人群高血糖和提高免疫力的营养组合物 | |
CN104519895B (zh) | 霞多丽种子产品的治疗用途 | |
CN101744170B (zh) | 一种适于糖尿病人的苦荞八宝粥及其制作方法 | |
CN110326780A (zh) | 一种具有降血糖功能的营养代餐及其制备方法 | |
CN102113648A (zh) | 一种适合“五高”代谢综合症人群的特膳面条及其制备方法 | |
MX2008015031A (es) | Metodos de uso y composiciones nutritivas de extracto de touchi. | |
Kochhar et al. | Effect of supplementation of traditional medicinal plants on blood glucose in non–insulin-dependent diabetics: A pilot study | |
CN101288466A (zh) | 夹心菌菇饼及其制备方法 | |
CN111011862B (zh) | 一种食用组合物、低血糖生成指数营养粉及其制备方法 | |
CN105876585A (zh) | 蛋白质固体饮料、其制备方法及其应用 | |
CN107660798A (zh) | 膳食补充剂 | |
CN108392519A (zh) | 一种降血糖组合物及其制备和应用 | |
CN104872677A (zh) | 一种有助于益生菌在宿主体内定植和增殖的膳食组合物及其应用 | |
Wahlqvist | Food and nutrition | |
CN104938580A (zh) | 低脂营养型月饼 | |
CN102113652A (zh) | 一种适合“五高”代谢综合症人群的特膳挤压米及其制备方法 | |
CN112352806A (zh) | 一种适用于糖尿病人的降糖人参蛋白棒及其制作方法 | |
CN110251655A (zh) | 一种用于治疗糖尿病的药物组合物及其制备方法 | |
RU2619223C2 (ru) | Профилактика или лечение избыточной массы и ожирения у пациентов с диабетом 2 типа | |
CN111543605A (zh) | 一种四高或肥胖人群用综合营养粉 | |
Yampolsky et al. | Kiwi (lat. Actinidia chinensis) | |
CN103110097A (zh) | 降压食疗品 | |
CN112971154A (zh) | 一种富含水溶性膳食纤维及α-淀粉酶抑制剂的固体混合物及其制备方法、应用 | |
CN107348350A (zh) | 一种调节血糖的面条及其制备方法 | |
EP2294932B1 (en) | Carbohydrate mixture and the use thereof for preparing a product for oral or enteral nutrition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190108 |
|
RJ01 | Rejection of invention patent application after publication |